Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer.

British journal of cancer - 1 Apr 2026

Ree Anne Hansen, Bousquet Paula A, Visnovska Tina, Lüders Torben, Geisler Benjamin P, Wang Shixiong, Bordin Diana L, Nilsen Hilde L, Hamre Hanne M, Kersten Christian, Hofsli Eva, Guren Marianne G, Sorbye Halfdan, Berg Jens P, Flatmark Kjersti, Meltzer Sebastian

Abstract excerpt

BACKGROUND: The randomised METIMMOX trial evaluated short-course oxaliplatin-based chemotherapy alternating with nivolumab for metastatic microsatellite-stable/mismatch repair-proficient colorectal cancer. In a post hoc analysis, we investigated whether tumour mutations or patients' systemic inflammation might provide insights into responsiveness to the METIMMOX regimen. METHODS: Patients received either...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Microsatellite Instability

Share to Nivolumab

Share to Oxaliplatin

Share to Progression-Free Survival

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 41731117
DOI: 10.1038/s41416-026-03357-6
PMCID: PMC13036003

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer.PMID 41731117Read ↗

Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade.Semantic proximity Read ↗

First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial.Semantic proximity Read ↗

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal CancerSemantic proximity Read ↗

Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).Semantic proximity Read ↗

Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 studySemantic proximity Read ↗

The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors.Semantic proximity Read ↗

Updated outcomes and exploratory analysis of RENMIN-215: tislelizumab plus fruquintinib and fecal microbiota transplantation in refractory microsatellite stable metastatic colorectal cancerSemantic proximity Read ↗

Effect of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer: a prospective observation studySemantic proximity Read ↗

Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).Semantic proximity Read ↗

Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer.Semantic proximity Read ↗

Changes in serum CXCL13 levels are associated with outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based TreatmentSemantic proximity Read ↗

Prolonged response to pembrolizumab in BRAFV600E microsatellite stable metastatic colorectal cancer following an increase in tumor mutational burden.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.